HIV infection progresses to AIDS quicker in developing countries

April 27, 2004

The progression from HIV infection to AIDS and death from AIDS is more rapid in people living in developing countries than those living in the United States and Europe, according to researchers from the Johns Hopkins Bloomberg School of Public Health, the Armed Forces Research Institute of Medical Sciences and Chiang Mai University in Thailand. The researchers tracked the length of time between HIV infection and AIDS among young Thai men. They also studied the death rate of the men 5-7 years after their HIV infection, which was higher when compared to their counterparts in developed countries. The study, "The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion" is published in the May 2004 issue of the Journal of Acquired Immune Deficiency Syndrome.

"The importance of this study is that it demonstrates the survival and progression rates of HIV/AIDS from the time of HIV infection in a developing country and documents that the progression is more rapid than in the U.S. and Europe," said Kenrad E. Nelson, MD, corresponding author and a professor in the Department of Epidemiology.

The researchers evaluated 235 men, who seroconverted during their two years of military service in the Royal Thai Army from 1991-1995. All of the men were drafted at the age of 21. After five to seven years, 156 were alive, 77 had died and 2 could not be located. The five-year survival rate of the study participants was 82 percent.

The median time from HIV-1 seroconversion to clinical AIDS in the Thai study participants was 7.4 years. A 2000 study by the Collaborative Group on AIDS Incubation and HIV Survival, known as CASCADE, which studied over 13,000 persons in whom the time of HIV infection was documented found that the medium time after HIV infection to the development of AIDS for persons in Europe, North America and Australia was 11 years for study participants who were 15-24 years old.

The mortality rate of the Thai men was 56.3 deaths per 1,000 person-years, or 18 percent five years after HIV-1 infection, as compared to a 9 percent mortality rate among individuals living in Western developed countries.

"These data will be very useful as treatment of HIV and opportunistic infections become more available for persons in developing countries. We will be able to measure the treatment's effect on progression and survival after HIV infection," said Dr. Nelson, who said that he would like to do a follow-up study on this cohort of men.
-end-
The study was supported by Cooperative Agreement DAMD17-98-2-7007 between the U.S. Army Medical Research and Material Command and the Henry M. Jackson Foundation for the Advancement of Military Medicine. Additional support came from the Johns Hopkins University Fogarty AITRP grant.

Chris Beyrer, in the Department of Epidemiology, co-authored the article, in addition to Ram Rangsin, Joseph Chiu, Chirasak Khamboonruang, Narongrid Sirisopana, Sakol Eiumtrakul, Arthur E. Brown, Merlin Robb, Cholticha Roengyutikarn and Lauri E. Markowitz.

To receive news releases from the Johns Hopkins Bloomberg School of Public Health via email, visit http://www.jhsph.edu/Press_Room.

Johns Hopkins University Bloomberg School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.